Bausch Health Companies (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Key Stats

• Today's Range: $5.32 to $5.48
• 50-Day Range: $4.33 to $7.71
• 52-Week Range: $3.96 to $9.85
• Volume: 1.35 million shs
• Average Volume: 2.71 million shs
• Market Capitalization: $1.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.17
• Consensus Rating: Reduce

Bausch Health Companies Stock Analysis - MarketRank™

Bausch Health Companies scored higher than 82% of companies evaluated by MarketBeat, and ranked 184th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Bausch Health Companies has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bausch Health Companies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.67%

Earnings Growth

Earnings for Bausch Health Companies are expected to grow by 5.67% in the coming year, from $4.41 to $4.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Companies is -45.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Companies is -45.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bausch Health Companies has a PEG Ratio of 0.37. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of Bausch Health Companies has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Companies has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Companies has recently increased by 29.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch Health Companies does not currently pay a dividend.

Dividend Growth

Bausch Health Companies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.42

Percentage of Shares Shorted

2.69% of the float of Bausch Health Companies has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Companies has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Companies has recently increased by 29.54%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

Bausch Health Companies has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Bausch Health Companies this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.12% of the stock of Bausch Health Companies is held by insiders.

Percentage Held by Institutions

78.65% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BHC Stock Analysis - Frequently Asked Questions

How have BHC shares performed this year?

Bausch Health Companies' stock was trading at $8.06 on January 1st, 2025. Since then, BHC stock has decreased by 32.8% and is now trading at $5.42.
View the best growth stocks for 2025 here.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) posted its earnings results on Wednesday, February, 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by $0.44. The firm earned $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative trailing twelve-month return on equity of 577.82% and a negative net margin of 0.48%.
Read the conference call transcript.

Who are Bausch Health Companies' major shareholders?

Top institutional investors of Bausch Health Companies include SG Americas Securities LLC (0.78%), Intact Investment Management Inc. (0.05%), Range Financial Group LLC (0.04%) and Kendall Capital Management.
View institutional ownership trends.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Companies investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Tesla (TSLA), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 4/25/2025
• Next Earnings (Estimated): 4/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHC
• CIK: 885590
• Web: www.bauschhealth.com
• Phone: (514) 744-6792
• Fax: 514-744-6272
• Employees: 19,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.17
• High Stock Price Target: $8.50
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +32.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.23
• P/E Growth: 0.37
• Net Income: $-46,000,000.00
• Net Margins: -0.48%
• Pretax Margin: 1.74%
• Return on Equity: -577.82%
• Return on Assets: 5.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $9.63 billion
• Price / Sales: 0.21
• Cash Flow: $5.75 per share
• Price / Cash Flow: 0.94
• Book Value: ($0.89) per share
• Price / Book: -6.07

Miscellaneous

• Outstanding Shares: 367,934,000
• Free Float: 338,058,000
• Market Cap: $1.99 billion
• Optionable: Optionable
• Beta: 0.43